Tafro syndrome: Critical review for clinicians and pathologists

PAYDAŞ S.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, cilt.128, ss.88-95, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 128
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.critrevonc.2018.05.015
  • Dergi Adı: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.88-95
  • Anahtar Kelimeler: TAFRO, Castleman disease, Anasarca, Fever, Reticulin fibrosis, Organomegaly, MULTICENTRIC CASTLEMAN-DISEASE, ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, KOJIMA DISEASE, CYCLOSPORINE-A, IMMUNE THROMBOCYTOPENIA, DIAGNOSTIC-CRITERIA, VARIANT, ANASARCA, TOCILIZUMAB, PATIENT
  • Çukurova Üniversitesi Adresli: Evet

Özet

TAFRO is an acrostic and includes thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R) and organomegaly (O) (Takai et al., 2013). TAFRO syndrome has been described firstly by Takai in Japanese patients. However TAFRO cases have been reported from US, Europe and other countries (Takai et al., 2010; Iwaki et al., 2016; Abdo et al., 2014). Three major and at least one minor criteria and exclusion of infectious, rheumatologic and neoplastic diseases are required for the diagnosis of TAFRO. In fact TAFRO must be thought in clinically undiagnosed and unsolved problemmatic cases.